Position in ALKS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$4,932,083
+$1,287,744 QoQ
Shares Held
139,482
+7.1% QoQ
Ownership
0.083%
of shares outstanding
% of Portfolio
1.29%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026DAFNA Capital Management LLC holds $21,126,826 across 6 Drug Manufacturers - Specialty & Generic names. ALKS ranks #2 (23.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
70,615 | $9,302,820 | |
| 2 | ALKS |
Alkermes plc.
This page
|
139,482 | $4,932,083 | |
| 3 | BCRX |
Biocryst Pharmaceuticals Inc
|
430,248 | $4,095,960 | |
| 4 | AQST |
Aquestive Therapeutics, Inc.
|
368,415 | $1,528,922 | |
| 5 | SCYX |
Scynexis Inc
|
1,086,956 | $996,738 | |
| 6 | ADCT |
ADC Therapeutics SA
|
72,081 | $270,303 |
All Filings in ALKS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,932,083 | 139,482 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,644,339 | 130,248 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $4,042,440 | 134,748 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $2,968,230 | 103,748 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $3,110,484 | 94,200 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $3,471,332 | 120,700 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $3,378,393 | 120,700 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $2,908,870 | 120,700 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||